1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Towa Pharmaceutical Co., Ltd.

Towa Pharmaceutical Co., Ltd.

TWAPF
Towa Pharmaceutical Co., Ltd.US flagOther OTC
26.00
USD
- -
- -
1.28BMarket Cap

Total Valuation

Towa Pharmaceutical Co., Ltd. carries a market capitalization of 1.28B, placing it among publicly traded companies globally. Its enterprise value stands at 351.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.28B
Enterprise Value351.60B

Share Statistics

Towa Pharmaceutical Co., Ltd. currently has 49.23M shares outstanding.

Shares Outstanding49.23M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Towa Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 18.69. The price-to-sales ratio is 1.43, and the price-to-book ratio stands at 1.19.

PE Ratio18.69
PS Ratio1.43
PB Ratio1.19
P/TBV Ratio1.54
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Towa Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 33.03 and an EV/FCF ratio of 1,002.70. The EV/Sales ratio of 2.92 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 33.03 provides insight into valuation relative to core operating earnings.

EV / Sales2.92
EV / EBITDA33.03
EV / EBIT33.03
EV / FCF1,002.70

Financial Position

Towa Pharmaceutical Co., Ltd. maintains a current ratio of 3.04, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 138.64, indicating elevated leverage, while an interest coverage ratio of 19.90 demonstrates strong ability to service its debt obligations.

Current Ratio3.04
Quick Ratio0.55
Debt / Equity138.64
Debt / EBITDA20.72
Interest Coverage19.90

Financial Efficiency

Towa Pharmaceutical Co., Ltd. posts a return on equity of 6.69 and a return on invested capital of 1.94.

Return on Equity (ROE)6.69
Return on Assets (ROA)2.21
Return on Invested Capital (ROIC)1.94
Return on Capital Employed (ROCE)2.81
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.75

Taxes

Over the trailing twelve months, Towa Pharmaceutical Co., Ltd. has paid 4.85B in income taxes, reflecting an effective tax rate of 34.46.

Income Tax4.85B
Effective Tax Rate34.46

Stock Price Statistics

Towa Pharmaceutical Co., Ltd.'s stock has gained approximately 54.48604% over the past 52 weeks. The 50-day moving average sits at 19.03, while the 200-day moving average is 17.38.

Beta (5Y)N/A
52-Week Price Change54.48604%
50-Day Moving Average19.03
200-Day Moving Average17.38
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Towa Pharmaceutical Co., Ltd. generated 120.54B in revenue and converted that into 9.22B in net income, yielding earnings per share of 187.32. EBITDA reached 10.65B, while operating income came in at 10.65B.

Revenue120.54B
Gross Profit43.14B
Operating Income10.65B
Pretax Income14.07B
Net Income9.22B
EBITDA10.65B
EBIT10.65B
Earnings Per Share (EPS)187.32

Balance Sheet

Towa Pharmaceutical Co., Ltd. holds 41.27B in cash and equivalents against 220.60B in total debt, resulting in a net debt position of 172.13B. Total book value stands at 144.26B, with working capital of 152.54B providing operational flexibility.

Cash & Cash Equivalents41.27B
Total Debt220.60B
Net Debt172.13B
Equity (Book Value)144.26B
Book Value Per Share2,930.96
Working Capital152.54B

Margins

Towa Pharmaceutical Co., Ltd. operates with a gross margin of 35.79, reflecting its pricing power and cost economics. The operating margin of 8.83 and net profit margin of 7.65 provide insight into operational efficiency.

Gross Margin35.79
Operating Margin8.83
Pretax Margin11.67
Profit Margin7.65
EBITDA Margin8.83

Scores

Towa Pharmaceutical Co., Ltd. posts an Altman Z-Score of 1.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.71